WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584681
Description: Mafoprazine is an antipsychotic drug with antiapomorphine and anti-methamphetamine actions.
MedKoo Cat#: 584681
Chemical Formula: C22H28FN3O3
Exact Mass: 401.2115
Molecular Weight: 401.4824
Elemental Analysis: C, 65.82; H, 7.03; F, 4.73; N, 10.47; O, 11.95
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
IUPAC/Chemical Name: 4'-(3-(4-(o-Fluorophenyl)-1-piperazinyl)propoxy)-m-acetanisidide
InChi Key: PHOCQBYGUQPMIB-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H28FN3O3/c1-17(27)24-18-8-9-21(22(16-18)28-2)29-15-5-10-25-11-13-26(14-12-25)20-7-4-3-6-19(20)23/h3-4,6-9,16H,5,10-15H2,1-2H3,(H,24,27)
SMILES Code: CC(NC1=CC=C(OCCCN2CCN(C3=CC=CC=C3F)CC2)C(OC)=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 401.4824 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Yamamura M, Nakagawa H, Maeda K, Kinoshita K, Ishida R. Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system. Jpn J Pharmacol. 1989 Jul;50(3):295-305. PubMed PMID: 2569544.
2: Yamamura M, Nakagawa H, Kinoshita K, Ochiai T, Ishida R. A behavioral pharmacological study of mafoprazine, a new phenylpiperazine derivative. Jpn J Pharmacol. 1988 Oct;48(2):203-12. PubMed PMID: 3210446.
3: Fukuchi I, Kawashima K, Matsuoka Y, Ishida R. Neurochemical study of mafoprazine, a new phenylpiperazine derivative. Jpn J Pharmacol. 1988 May;47(1):51-61. PubMed PMID: 3411821.
4: Rao TS, Mick SJ, Cler JA, Emmett MR, Dilworth VM, Contreras PC, Gray NM, Wood PL, Iyengar S. Effects of sigma ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: further evidence for a functional modulation of N-methyl-D-aspartate (NMDA) receptor complex-mediated events by sigma ligands. Brain Res. 1991 Oct 4;561(1):43-50. PubMed PMID: 1686745.